Click the Why column to see why an item matched the search.
Match | Type | Why |
---|
KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition. | Academic Article |
Why?
|
EGFR-mediated chromatin condensation protects KRAS-mutant cancer cells against ionizing radiation. | Academic Article |
Why?
|
Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma. | Academic Article |
Why?
|
KrasP34R and KrasT58I mutations induce distinct RASopathy phenotypes in mice. | Academic Article |
Why?
|
MEK and TAK1 Regulate Apoptosis in Colon Cancer Cells with KRAS-Dependent Activation of Proinflammatory Signaling. | Academic Article |
Why?
|
TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers. | Academic Article |
Why?
|
Adaptive and Reversible Resistance to Kras Inhibition in Pancreatic Cancer Cells. | Academic Article |
Why?
|
Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors. | Academic Article |
Why?
|
Early Intervention in Lung Cancers With Rapid Plasma Genotyping for EGFR and KRAS Mutations-Reply. | Academic Article |
Why?
|
KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases. | Academic Article |
Why?
|
KRAS mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome. | Academic Article |
Why?
|
KRAS mutation status, comorbidity, and mortality in patients with metastatic colorectal cancer in Denmark. | Academic Article |
Why?
|
KRAS wild-type lung cancer: a moving target in an era of genotype migration. | Academic Article |
Why?
|
Mutations in RABL3 alter KRAS prenylation and are associated with hereditary pancreatic cancer. | Academic Article |
Why?
|
Organoids Model Transcriptional Hallmarks of Oncogenic KRAS Activation in Lung Epithelial Progenitor Cells. | Academic Article |
Why?
|